Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: Results from the phase III, randomized ATLAS trial

M. Gross-Goupil, T. G. Kwon, M. Eto, D. Ye, H. Miyake, S. I. Seo, S. S. Byun, J. L. Lee, V. Master, J. Jin, R. DeBenedetto, R. Linke, M. Casey, B. Rosbrook, M. Lechuga, O. Valota, E. Grande, D. I. Quinn

Research output: Contribution to journalArticlepeer-review

67 Citations (Scopus)

Fingerprint Dive into the research topics of 'Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: Results from the phase III, randomized ATLAS trial'. Together they form a unique fingerprint.

Medicine & Life Sciences